(vianews) - vistin pharma (vistn.ol) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| vistin pharma (vistn.ol) | kr22.60 | 3.11% | 16.03% |
| ipsen (ipn.pa) | €99.95 | 1.08% | 12.52% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. vistin pharma (vistn.ol)
3.11% forward dividend yield and 16.03% return on equity
vistin pharma asa, through its subsidiary, vistin pharma as, produces and sells active pharmaceutical ingredients (apis) worldwide. it offers metformin hcl apis and direct compressive granulates for the pharmaceutical industry. the company was founded in 1969 and is headquartered in oslo, norway.
earnings per share
as for profitability, vistin pharma has a trailing twelve months eps of kr1.
pe ratio
vistin pharma has a trailing twelve months price to earnings ratio of 22.6. meaning, the purchaser of the share is investing kr22.6 for every norwegian krone of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.03%.
moving average
vistin pharma's value is under its 50-day moving average of kr23.13 and under its 200-day moving average of kr23.02.volume
today's last reported volume for vistin pharma is 4472 which is 68.5% below its average volume of 14201.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, vistin pharma's stock is considered to be oversold (<=20).
more news about vistin pharma.
2. ipsen (ipn.pa)
1.08% forward dividend yield and 12.52% return on equity
ipsen s.a. operates as a biopharmaceutical company worldwide. the company provides drugs in the areas of oncology, neuroscience, and rare diseases. its product pipeline comprises cabometyx + atezolizumab, which is in phase iii clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and taverik, which is in phase iii for the treatment of second line follicular lymphoma; bylvay, which is in phase iii for the treatment of biliary atresia; dysport, which is in phase iii clinical trial for the treatment of chronic and episodic migraine; fidrisertib, which is in phase ii clinical trial for the treatment of fibrodysplasia ossificans progressiva; elafibranor, which is in phase ii for the treatment of primary sclerosing cholangitis, as well as ipn60250; ipn10200, which is in phase ii for the treatment of longer-acting neurotoxin aesthetics and therapeutics; ipn60210, which is in phase i clinical trial for the treatment of relapsed/refractory multiple myeloma; and ipn60260 for the treatment of viral cholestatic disease and is in phase i clinical trial. the company also offers somatuline, decapeptyl, cabometyx, onivyde, tazverik, and other oncology products; dysport and other neurosciences products; and bylvay, nutropinaq, increlex, and sohonos for rare diseases. the company was founded in 1929 and is based in boulogne-billancourt, france.
earnings per share
as for profitability, ipsen has a trailing twelve months eps of €7.4.
pe ratio
ipsen has a trailing twelve months price to earnings ratio of 13.51. meaning, the purchaser of the share is investing €13.51 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.52%.
revenue growth
year-on-year quarterly revenue growth grew by 8.4%, now sitting on 3.28b for the twelve trailing months.
more news about ipsen.